Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US study raises doubts over ovarian cancer tests

This article was originally published in Clinica

Executive Summary

Two methods commonly used to screen women for ovarian cancer may also cause unnecessary surgery, due to the high level of false positive results caused by the tests. So found preliminary data from one of the largest screening trials of its kind - the PLCO Cancer Screening Trial - which was set up by the US National Cancer Institute (NCI) in 1993 to investigate the long-term benefit of cancer screening tests for prostate, lung, colorectal and ovarian cancer (PLCO).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT056962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel